102. The palm is ~0.5% TBSA - Insurance companies denying coverage - Malignancy risk in JAK inhibitors - MACE risk in JAK inhibitors - Oral azoles for head-and-neck dermatitis

The palm is ~0.5% TBSA [article]

Insurance companies denying coverage [article]

Malignancy risk in JAK inhibitors [article]

MACE risk in JAK inhibitors [article]

Oral azoles for head-and-neck dermatitis [article]

Luke's PDPC course and the Intermountain Derm Society meeting: https://registration.socio.events/e/idspdpc23/promo-codes/ATTENDEE

Connect with us!

- Web: https://dermaspherepodcast.com/

- Twitter: @DermaspherePC

- Instagram: dermaspherepodcast

- Facebook: https://www.facebook.com/DermaspherePodcast/

- Check out Luke and Michelle’s other podcast, SkinCast! https://healthcare.utah.edu/dermatology/skincast/

Luke and Michelle report no significant conflicts of interest… BUT check out our friends at:

- Kikoxp.com(a social platform for doctors to share knowledge)

- https://www.levelex.com/games/top-derm (A free dermatology game to learn more dermatology!)